Mi SciELO
Servicios Personalizados
Revista
Articulo
Indicadores
Citado por SciELO
Accesos
Links relacionados
Citado por Google
Similares en SciELO
Similares en Google
Compartir
Archivos de la Sociedad Española de Oftalmología
versión impresa ISSN 0365-6691
Resumen
ALVAREZ-RIVERA, L.G. et al. Coat's disease treated with bevacizumab (Avastin®). Arch Soc Esp Oftalmol [online]. 2008, vol.83, n.5, pp.329-331. ISSN 0365-6691.
Case Report: We report a case of Coats disease in a 10-year-old-girl who presented with a profound visual deficit, exudative retinal detachment, vascular telangiectasias and subretinal lipid, who underwent treatment with an intravitreal injection of bevacizumab (AVASTIN™). Serial examinations documented an involutional response with a reduction of the subretinal fluid, exudates and macular thickness. Discussion: The aetiology of Coats disease remains uncertain, as does its optimal management. Although resolution of a case depends partially on age, and can even occur spontaneously on rare occasions, intravitreal injections of bevacizumab should be considered when planning treatment.
Palabras clave : Vascular endothelial growth factor; Coats disease; monoclonal antibodies; angiogenesis inhibitors; telangiectatic retinal vessels.